Nearly half of participants were able to engage in normal physical activity without angina at 6 months post-treatment.
Breyanzi is currently approved for the second-line or later treatment of large B-cell lymphomas.
Patients continued to show statistically significant upper limb performance improvements.
Iovance is on track to complete its rolling BLA submission for lifileucel in the post-anti-PD1 melanoma indication in the first quarter of 2023.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.